Telix Pharmaceuticals Limited

TLX | NASDAQ

$11.94

+$0.63 (+5.57%)

Sep 22, 2026, 12:50 PM ET · Market open

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Net Income	-10.69M	49.92M	5.21M	-104.08M	-80.51M	-44.89M
Depreciation & Amortization	32.67M	8.02M	6.74M	5.38M	5.17M	4.88M
Stock-Based Compensation	n/a	19.66M	8.79M	8.11M	1.32M	2.35M
Other Working Capital	-69.12M	-38.51M	-20.52M	-3.69M	2.6M	-193K
Other Non-Cash Items	19.89M	64.26M	60.68M	55.26M	22.1M	40.23M
Deferred Income Tax	n/a	n/a	n/a	n/a	n/a	n/a
Change in Working Capital	-67.81M	-98.82M	-57.53M	-28.64M	-7.42M	-612K
Operating Cash Flow	-25.93M	43.03M	23.88M	-63.97M	-59.33M	1.96M
Capital Expenditures	-56.86M	-14.32M	-9.68M	-7.04M	-1.34M	-248K
Cash Acquisitions	-330.92M	-34.69M	-1.48M	-973K	n/a	-322K
Purchase of Investments	-1.34M	n/a	n/a	n/a	n/a	n/a
Sales Maturities Of Investments	n/a	n/a	n/a	n/a	n/a	n/a
Other Investing Acitivies	-12.55M	-86.16M	-14.33M	-8.99M	-1.39M	-521K
Investing Cash Flow	-428.79M	-135.17M	-25.49M	-17M	-2.73M	-1.09M
Debt Repayment	-434.9K	652.81M	3.53M	1.74M	-936K	-904K
Common Stock Repurchased	n/a	n/a	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	-7.85M	-13.89M	6.65M	173.22M	3.78M	35.02M
Financial Cash Flow	-5.58M	638.92M	10.19M	174.96M	2.85M	34.12M
Net Cash Flow	-446.35M	587.11M	6.91M	94.29M	-55.91M	33.35M
Free Cash Flow	-82.8M	28.71M	14.21M	-71.01M	-60.67M	1.71M
Adj. Free Cash Flow	-82.8M	9.05M	5.42M	-79.12M	-61.99M	-634K
Maintenance CapEx	-10.98M	n/a	n/a	n/a	n/a	n/a
Growth CapEx	-45.88M	-14.32M	-9.68M	-7.04M	-1.34M	-248K
Owner Earnings	-36.91M	43.03M	23.88M	-63.97M	-59.33M	1.96M